1-2 of 2
Kallappa Koti
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

U.S. Food and Drug Administration Approval Summary: Brentuximab Vedotin for the Treatment of Relapsed Hodgkin Lymphoma or Relapsed Systemic Anaplastic Large-Cell Lymphoma

R. Angelo de Claro, Karen McGinn, Virginia Kwitkowski, Julie Bullock, Aakanksha Khandelwal, Bahru Habtemariam, Yanli Ouyang, Haleh Saber, Kyung Lee, Kallappa Koti, Mark Rothmann, Marjorie Shapiro, Francisco Borrego, Kathleen Clouse, Xiao Hong Chen, Janice Brown, Lara Akinsanya, Robert Kane, Edvardas Kaminskas, Ann Farrell, Richard Pazdur
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (21): 5845–5849.
https://doi.org/10.1158/1078-0432.CCR-12-1803
Published: 06 November 2012
View article titled, U.S. Food and Drug Administration Approval Summary: Brentuximab Vedotin for the Treatment of Relapsed Hodgkin Lymphoma or Relapsed Systemic Anaplastic Large-Cell Lymphoma
Open the PDF for U.S. Food and Drug Administration Approval Summary: Brentuximab Vedotin for the Treatment of Relapsed Hodgkin Lymphoma or Relapsed Systemic Anaplastic Large-Cell Lymphoma in another window
Journal Articles

U.S. Food and Drug Administration Approval: Panitumumab for Epidermal Growth Factor Receptor–Expressing Metastatic Colorectal Carcinoma with Progression Following Fluoropyrimidine-, Oxaliplatin-, and Irinotecan-Containing Chemotherapy Regimens

Ruthann M. Giusti, Kaushikkumar Shastri, Anne M. Pilaro, Chana Fuchs, Ruth Cordoba-Rodriguez, Kallappa Koti, Mark Rothmann, Angela Yuxin Men, Hong Zhao, Monica Hughes, Patricia Keegan, Karen D. Weiss, Richard Pazdur
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (5): 1296–1302.
https://doi.org/10.1158/1078-0432.CCR-07-1354
Published: 03 March 2008
View article titled, U.S. Food and Drug Administration Approval: Panitumumab for Epidermal Growth Factor Receptor–Expressing Metastatic Colorectal Carcinoma with Progression Following Fluoropyrimidine-, Oxaliplatin-, and Irinotecan-Containing Chemotherapy Regimens
Open the PDF for U.S. Food and Drug Administration Approval: Panitumumab for Epidermal Growth Factor Receptor–Expressing Metastatic Colorectal Carcinoma with Progression Following Fluoropyrimidine-, Oxaliplatin-, and Irinotecan-Containing Chemotherapy Regimens in another window